These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
364 related articles for article (PubMed ID: 12702581)
1. Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor. Vu TH; Chuyen NV; Li T; Hoffman AR Cancer Res; 2003 Apr; 63(8):1900-5. PubMed ID: 12702581 [TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor II and WT1 transcript localization in human fetal kidney and Wilms' tumor. Yun K; Fidler AE; Eccles MR; Reeve AE Cancer Res; 1993 Nov; 53(21):5166-71. PubMed ID: 8221652 [TBL] [Abstract][Full Text] [Related]
3. Aberrant imprinting of the insulin-like growth factor II receptor gene in Wilms' tumor. Xu YQ; Grundy P; Polychronakos C Oncogene; 1997 Mar; 14(9):1041-6. PubMed ID: 9070652 [TBL] [Abstract][Full Text] [Related]
4. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Steenman MJ; Rainier S; Dobry CJ; Grundy P; Horon IL; Feinberg AP Nat Genet; 1994 Jul; 7(3):433-9. PubMed ID: 7920665 [TBL] [Abstract][Full Text] [Related]
5. Alterations in the promoter-specific imprinting of the insulin-like growth factor-II gene in Wilms' tumor. Vu TH; Hoffman A J Biol Chem; 1996 Apr; 271(15):9014-23. PubMed ID: 8621549 [TBL] [Abstract][Full Text] [Related]
6. Expression, promoter usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. Li X; Adam G; Cui H; Sandstedt B; Ohlsson R; Ekström TJ Oncogene; 1995 Jul; 11(2):221-9. PubMed ID: 7624139 [TBL] [Abstract][Full Text] [Related]
7. Mosaic allelic insulin-like growth factor 2 expression patterns reveal a link between Wilms' tumorigenesis and epigenetic heterogeneity. Ohlsson R; Cui H; He L; Pfeifer S; Malmikumpu H; Jiang S; Feinberg AP; Hedborg F Cancer Res; 1999 Aug; 59(16):3889-92. PubMed ID: 10463576 [TBL] [Abstract][Full Text] [Related]
8. Altered specificity of IGF2 promoter imprinting during fetal development and onset of Wilms tumour. Taniguchi T; Schofield AE; Scarlett JL; Morison IM; Sullivan MJ; Reeve AE Oncogene; 1995 Aug; 11(4):751-6. PubMed ID: 7651739 [TBL] [Abstract][Full Text] [Related]
9. Loss of imprinting of the insulin-like growth factor II gene in renal cell carcinoma. Nonomura N; Nishimura K; Miki T; Kanno N; Kojima Y; Yokoyama M; Okuyama A Cancer Res; 1997 Jul; 57(13):2575-7. PubMed ID: 9205056 [TBL] [Abstract][Full Text] [Related]
10. Relaxation of IGF2 imprinting in Wilms tumours associated with specific changes in IGF2 methylation. Sullivan MJ; Taniguchi T; Jhee A; Kerr N; Reeve AE Oncogene; 1999 Dec; 18(52):7527-34. PubMed ID: 10602511 [TBL] [Abstract][Full Text] [Related]
11. Increased expression of the insulin-like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity. Wang WH; Duan JX; Vu TH; Hoffman AR J Biol Chem; 1996 Nov; 271(44):27863-70. PubMed ID: 8910385 [TBL] [Abstract][Full Text] [Related]
12. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Ogawa O; Eccles MR; Szeto J; McNoe LA; Yun K; Maw MA; Smith PJ; Reeve AE Nature; 1993 Apr; 362(6422):749-51. PubMed ID: 8097018 [TBL] [Abstract][Full Text] [Related]
13. Comparative reverse transcription-polymerase chain reaction and in situ hybridization analyses of human imprinted p57KIP2 and insulin-like growth factor 2 gene transcripts in fetal kidney and Wilms' tumors using archival tissue. Soejima H; McLay J; Hatada I; Mukai T; Jinno Y; Niikawa N; Yun K Lab Invest; 1998 Jan; 78(1):19-28. PubMed ID: 9461119 [TBL] [Abstract][Full Text] [Related]
15. Loss of imprinting of IGF2 in Ewing's sarcoma. Zhan S; Shapiro DN; Helman LJ Oncogene; 1995 Dec; 11(12):2503-7. PubMed ID: 8545106 [TBL] [Abstract][Full Text] [Related]
16. Loss of imprinting in hepatoblastoma. Rainier S; Dobry CJ; Feinberg AP Cancer Res; 1995 May; 55(9):1836-8. PubMed ID: 7728748 [TBL] [Abstract][Full Text] [Related]
17. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor. Watanabe N; Nakadate H; Haruta M; Sugawara W; Sasaki F; Tsunematsu Y; Kikuta A; Fukuzawa M; Okita H; Hata J; Soejima H; Kaneko Y Genes Chromosomes Cancer; 2006 Jun; 45(6):592-601. PubMed ID: 16518847 [TBL] [Abstract][Full Text] [Related]
18. Inactivation of H19, an imprinted and putative tumor repressor gene, is a preneoplastic event during Wilms' tumorigenesis. Cui H; Hedborg F; He L; Nordenskjöld A; Sandstedt B; Pfeifer-Ohlsson S; Ohlsson R Cancer Res; 1997 Oct; 57(20):4469-73. PubMed ID: 9377554 [TBL] [Abstract][Full Text] [Related]
19. Promoter-specific imprinting of the human insulin-like growth factor-II gene. Vu TH; Hoffman AR Nature; 1994 Oct; 371(6499):714-7. PubMed ID: 7935819 [TBL] [Abstract][Full Text] [Related]
20. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors. Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]